Welcome to our dedicated page for Lite Strategy news (Ticker: LITS), a resource for investors and traders seeking the latest updates and insights on Lite Strategy stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lite Strategy's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lite Strategy's position in the market.
Lite Strategy (NASDAQ: LITS) announced on October 29, 2025 that its Board authorized a $25 million share repurchase program effective immediately. The program permits open-market and negotiated buybacks and may be executed under a future Rule 10b5-1 trading plan to allow purchases outside normal trading windows. The company said repurchases will be funded from available working capital and that timing and amounts will depend on market conditions; the program has no set price targets or timetable and may be suspended or terminated. Management highlighted flexibility to buy shares when trading below mNAV and to sell via its at-the-market offering when shares trade at a premium to mNAV.
Lite Strategy (NASDAQ: LITS) marked the 14th anniversary of Litecoin on October 16, 2025, highlighting Litecoin’s longevity as the second-longest-running blockchain and its transaction history.
Lite Strategy says it is the first U.S.-listed public company to adopt Litecoin as its primary reserve asset, positioning LITS as a regulated, public-market vehicle for institutional exposure to Litecoin. Management frames the move as an immediate alternative while some digital asset ETFs remain pending amid an ongoing government shutdown.
MEI Pharma (NASDAQ:MEIP) announced its corporate rebranding to Lite Strategy, Inc. and will change its ticker to LITS effective September 11, 2025. The transformation reflects the company's strategic pivot to digital asset treasury management, focusing on Litecoin (LTC) as its primary reserve asset.
The company has already secured over $100 million in LTC with guidance from Litecoin creator Charlie Lee, who serves on the board, and GSR Ventures. While embracing this new direction, Lite Strategy continues to maintain its pharmaceutical pipeline, evaluating development opportunities for voruciclib and zandelisib.
FAQ
What is the current stock price of Lite Strategy (LITS)?
What is the market cap of Lite Strategy (LITS)?
